NCT02235740View on ClinicalTrials.gov

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Cancer

Interventions

DRUG

Afuresertib

Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.

DRUG

Carfilzomib

Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder

Trial Locations (1)

27518

Novartis Investigative Site, Cary